Adhesive remover with antiseptic tea tree oil gently helps to remove pouches and to clean up any adhesive residue from the skin.

Cutimed Protect is a liquid skin protectant. Sprayed on as a liquid, it forms a durable, waterproof barrier film. This creates a protective barrier that prevents skin irritation due to adhesive products, shearing forces, or bodily fluids. For use on intact or irritated skin.

Cream is suitable for the care of patients with incontinence who are at risk of skin maceration and dermatitis. It moistures the skin and prevents it from drying out while keeping it permeable to water vapour and oxygen.

Provides an effective barrier to protect intact skin from the harmful effects of bodily fluids, such as wound exudate and excessive perspiration, as well as from friction, shear and adhesive trauma.

Facilitates the quick and easy removal of adhesive medical devices and dressings. It is suitable for use on intact and injured skin.

Polymeric solution that forms a uniform film when applied to the skin. Dispersed in a non-stinging solvent, which dries rapidly. Colourless, transparent and possesses good oxygen and moisture vapour permeability. Helps to protect intact or damaged skin from irritation caused by urine and/or faecal incontinence, digestive juices and wound drainage.

White concentrated cream that provides the skin with protection from body fluids. Also protects dry, chafed, red or irritated skin by moisturising the skin and providing a long-lasting barrier. Use still allows adhesive products to stick to the skin.

Water-repellent, antiseptic barrier cream containing 22% dimeticone and 0.1% benzalkonium chloride. Active against bacteria and yeasts.

Cocois is a combination of coal tar, salicylic acid and sulphur, which are widely used in the treatment of hyperkeratotic and scaling skin conditions. Coal tar is antipruritic, keratoplastic and a weak antiseptic. Salicylic acid has keratolytic properties. Sulphur is keratolytic, with weak antiseptic and parasiticide properties. Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk. Adverse events should also be reported to RPH Pharmaceuticals AB.

Biosimilar of adalimumab (Humira).